The analysis of serum for the presence of free light chains has become an important adjunct to testing by serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE) [1] . The first commercial free light chain assays using polyclonal reagents was released in 2001 by Binding Site Inc. (Freelite™). Subsequently, in 2011, Siemens released monoclonal-based free light chain assays. The interest in free light chain testing has increased with a more than doubling of the subscription rates to the College of American Proficiency Testing Survey from 2010. We validated the Diazyme free light chain assay, a latex particle enhanced immunoturbidimetric assay that uses polyclonal antibodies and was adapted to the Siemens Advia 1800 analyzer. As this assay was not FDA approved on this analyzer, we considered it as a "lab developed test." We conducted a clinical concordance study compared to the Freelite assay as the predicate.
the free λ assay was 90%, with most discordant results being near the cutoff concentration. If the Diazyme cutoff upper reference range is raised to 32.0 mg/L, the degree of concordance increase to 94% (all were positive by the Diazyme and negative by Binding Site assays). Among the discordant results, all but 2 patients (3 samples total) had result values near the cutoff concentration for the two assays. A review of the medical records showed that myeloma was present in both patients.
For the κ/ λ ratio, the degree of concordance using the manufacturer's recommended reference interval was 79%, with 47 discrepancies. For the purpose of this study, we varied the Diazyme reference range by lowering it from 0.22-1.74 to 0.19 to 1.50. The degree of concordance improved to 86% (1 low discordance and 29 high discordance). Among the discordant results, all but 6 had results near the cutoff ratio for these two assays (i.e., within the imprecision of the assay, of roughly 10%). All were positive for the Binding Site assay ratio and negative for the Diazyme assay ratio (3 with and 3 without myeloma). These discrepant patients were not the same as the two discordant patients using the free λ test. Use of a lower Diazyme cutoff would have resulted in more false positive results. We are not suggesting an alteration in the reference range recommended by Diazyme and approved by the FDA, as a reference range study was not conducted. By altering the cutoff, we wanted to show that the discordance between the two assays was likely imprecision of the assay at cutoff limits.
Previous reports have demonstrated a higher degree of clinical discordances between different manufacturers of free light reagents. In three of these studies, monoclonal antibodies were used as the reagent [2] [3] [4] , one non-commercial assay and two Siemens assay respectively. There were some discrepancies in the results of these two assays with some discussion written by scientists at Binding Site [5, 6] . In one of the rebuttals suggested that the cause of discrepancies could be the presence of amyloidosis or free light chains disease [5] . The discordant patients reported in this study were not among the 2 patients with amyloidosis or the 4 patients suffering from free light chain disease. Overall, we demonstrated less discordance of results probably because of the use of polyclonal antibodies in both assays. Given the heterogeneity of multiple myeloma expression, i.e., diversity within the variable domain region, use of polyclonal antibodies should capture more variant immunoglobulin forms. A future study is warranted to determine if differences between monoclonal vs. polyclonal-based free light chain assays have clinical relevance. It is often necessary for clinical laboratories to change the reagents used for a laboratory test or tests if different instruments are used, there is an alteration in the availability of reagents such as with an FDA recall, or for economic reasons. The guidelines for use of free light chains for myeloma diagnosis and monitoring were based on results obtained from the predicate assay (Binding Site). If there is concordance of results with a new manufacturer of reagents, it may be possible to substitute results of the new assay against the previous one following some clinical validation, as was performed in this study. However, each laboratory must conduct some validation studies for use of the new assay prior to use within their practice. This may be accompanied by a change in the reference ranges. The use of values approved by the FDA is preferred unless the laboratory has the means and rationale to conducting their own reference ranges studies. Simply adopting recommended new reference ranges are less of an issue for diagnostic tests where results are used in cross section, than for tests that are longitudinally used for monitoring disease. Changing manufacturers of tumor markers can be difficult due to heterogeneity of the marker, e.g., different degrees of glycosylations, results in a high degree of discordance [7] . For serial monitoring of myeloma patients, clinical laboratories switching from one assay to another may consider saving samples tested on prior free light chain reagents in order to "re-baseline" results from the new reagents. As discordant results are almost always present when changing reagents or methods, this approach would reduce misinterpretation of test results should outliers be present.
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